FDA recommends Zika testing for all blood donations

The FDA is advising all U.S. states and territories to screen donated blood and blood components for the Zika virus, a major expansion of screening efforts to prevent spread of the mosquito-borne virus through blood supplies.

Previously, the agency had also advised screening at blood banks in Puerto Rico and parts of Florida, where there have been cases of local Zika transmission. That was before a report from Brazilian researchers and the American Red Cross published in the New England Journal of Medicine said a donor had transmitted Zika to two hospitalized patients through a blood platelet transfusion in January 2016.

“There is still much uncertainty regarding the nature and extent of Zika virus transmission,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research. “At this time, the recommendation for testing the entire blood supply will help ensure that safe blood is available for all individuals who might need transfusion.”

The FDA says all parts of the U.S. where active transmission have been confirmed are in compliance with the previous guidance of screening donated whole blood and blood components for Zika, using pathogen-reduction devices, or halting blood collection and instead obtaining donations from areas where the virus isn’t actively being spread by mosquitoes.

This new alert recommends the entire county and U.S. territories use a FDA-authorized blood screening test or a licensed test on donated blood or blood components. A pathogen-reduction device could be used for plasma and other platelet products.

Blood centers could be testing for the virus for quite a while, as the agency said the recommendations “will be in effect until the risk of transfusion transmission of Zika virus is reduced.”

According to the most recent federal statistics, more than 10,000 cases of Zika have been confirmed in the U.S and its territories. The virus, which can be transmitted by mosquitoes or through sexual contact, can cause serious birth defects such as microcephaly, but four out of five adults who are infected never develop symptoms. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup